Sugi Predict
/ Targets
/ KSR2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to KSR2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer |
PHASE2/PHASE3 | COMPLETED |
| Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome |
PHASE3 | COMPLETED |
| NEO100 and High-Grade Meningioma |
PHASE2 | RECRUITING |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) |
PHASE2 | WITHDRAWN |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma |
PHASE2 | COMPLETED |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma |
PHASE2 | COMPLETED |
| Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases |
PHASE2 | UNKNOWN |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours |
PHASE1/PHASE2 | COMPLETED |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma |
PHASE1/PHASE2 | SUSPENDED |
| Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... |
PHASE2 | COMPLETED |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer |
PHASE1/PHASE2 | COMPLETED |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer |
PHASE2 | COMPLETED |
| Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma |
PHASE1/PHASE2 | COMPLETED |
| BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer |
PHASE1 | COMPLETED |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. |
PHASE1 | COMPLETED |
| FAK Inhibitor in Patients With Advanced Solid Tumors |
PHASE1 | NOT_YET_RECRUITING |
| Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer |
PHASE1 | COMPLETED |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Clinical Genetics Branch Eligibility Screening Survey |
nan | NOT_YET_RECRUITING |
| Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial |
nan | RECRUITING |
| RASopathy Biorepository |
nan | RECRUITING |
| Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
nan | ACTIVE_NOT_RECRUITING |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| Molecular Analysis of Thoracic Malignancies |
nan | ENROLLING_BY_INVITATION |
| Characterisation of Gene Variants in the Angiogenic Pathway |
nan | UNKNOWN |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a KSR2 binder may also engage these)